|1.||Jin, Tao: 4 articles (09/2013 - 10/2003)|
|2.||Bokarewa, Maria: 4 articles (10/2010 - 10/2003)|
|3.||Tarkowski, Andrej: 4 articles (01/2006 - 10/2003)|
|4.||Van de Werf, F: 3 articles (09/2003 - 05/2000)|
|5.||Collen, D: 3 articles (05/2001 - 05/2000)|
|6.||Monecke, Stefan: 2 articles (01/2015 - 11/2007)|
|7.||Ehricht, Ralf: 2 articles (01/2015 - 11/2007)|
|8.||Vergara, Patri: 2 articles (11/2014 - 07/2012)|
|9.||Josefsson, Elisabet: 2 articles (09/2013 - 10/2010)|
|10.||Su, Zhiguo: 2 articles (02/2013 - 05/2011)|
10/15/1995 - "Recombinant staphylokinase (STAR) was shown recently to offer promise for coronary arterial thrombolysis in patients with evolving myocardial infarction. "
06/01/2002 - "The recombinant PEG-modified SY161 staphylokinase is currently in phase II clinical trials as a treatment for acute myocardial infarction. "
05/01/2000 - "We undertook an angiographic, dose-finding study of staphylokinase (SAK42D variant) to evaluate its efficacy and safety in patients with acute ST-segment myocardial infarction. "
01/01/2000 - "The first clinical studies suggest that recombinant staphylokinase (Sak) constitutes an effective thrombolytic agent in the treatment of patients with myocardial infarction or peripheral arterial occlusion. "
02/11/2013 - "Here, staphylokinase (SAK), a thrombolysis agent for therapy of myocardial infarction, was mono-PEGylated at the C-terminus of SAK far from its bioactive domain. "
01/01/2007 - "Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits."
01/01/2011 - "New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats."
06/01/1996 - "The thrombolytic potencies of 50 micrograms/kg compound at baseline, assessed in an extracorporeal thrombosis model, were similar: 77 +/- 2.9% (mean +/- SEM) clot lysis in group 1 and 83 +/- 3.6% in group 2. Groups 1 and 2 were immunized subcutaneously at 2, 3, and 5 weeks with 500 micrograms SakSTAR or SakSTAR.M38, respectively. "
01/01/1995 - "Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis."
11/01/2008 - "Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity."
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
03/01/1998 - "Thus catheter-directed infusion of recombinant staphylokinase in patients with deep vein thrombosis appears feasible and may be associated with a high frequency of thrombolysis. "
03/01/1998 - "The feasibility of catheter-directed thrombolysis with recombinant staphylokinase was evaluated in six selected patients with deep vein thrombosis. "
03/01/1998 - "Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis."
10/01/1991 - "Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis."
01/01/1998 - "Newer molecules such as pro-urokinase, saruplase, alteplase, K1K2Pu and staphylokinase have shown promise in animal models of arterial and venous thrombosis and also in pilot scale clinical studies in patients with myocardial infarction. "
12/01/2015 - "Staphylokinase and ABO group phenotype: new players in Staphylococcus aureus implant-associated infections development."
10/15/2014 - "Limitations of staphylokinase as a marker for Staplylococcus aureus invasive infections in humans."
09/01/2013 - "Staphylokinase promotes the establishment of Staphylococcus aureus skin infections while decreasing disease severity."
11/01/2009 - "Expulsion of secondary Trichinella spiralis infection in rats occurs independently of mucosal mast cell release of mast cell protease II."
10/01/2003 - "Fatal outcome of bacteraemic patients caused by infection with staphylokinase-deficient Staphylococcus aureus strains."
02/01/1994 - "The protective effects, which were dose dependent, caused a significant reduction of inflammation in the lamina propria, reduction of the necrosis of intestinal epithelial cells, and complete inhibition of toxin A-mediated release of rat mast cell protease II, a specific product of rat mucosal mast cells. "
01/01/1993 - "In conventional rats, we have previously demonstrated that corticosteroid treatment caused macrophage engulfment and destruction of intestinal mucosal mast cells and eosinophils by 24 h without evidence of local tissue destruction, inflammation or secretion of rat mast cell protease II. As the growth and survival of these cells appear to be dependent on factors derived from T lymphocytes, we examined the response in congenitally athymic rnu/rnu rats and euthymic rnu/+ rats 35 days after parasitic infection. "
|1.||Tissue Plasminogen Activator (Alteplase)
|6.||Plasminogen Activators (Plasminogen Activator)
|7.||Fibrinolytic Agents (Antithrombotic Agents)